055398212	055398212	CD	B-NP	O
|	|	NN	I-NP	O
FH	FH	NN	I-NP	O
|	|	NN	I-NP	O
16337084	16337084	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
5385680	5385680	CD	B-NP	O
|	|	CC	I-NP	O
1/17/2006	1/17/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
PNEUMONIA	PNEUMONIA	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Unsigned	Unsigned	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
2/24/2006	2/24/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Unsigned	Unsigned	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/9/2006	8/9/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
DUPES	DUPES	NNS	B-NP	O
,	,	,	O	O
FERNANDO	FERNANDO	NNP	B-NP	O
B.	B.	NNP	I-NP	O
TEAM	TEAM	NNP	I-NP	O
:	:	:	O	O
S	S	NNP	B-NP	O
Terchu	Terchu	NNP	I-NP	O
Fay	Fay	NNP	I-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
condition	condition	NN	I-NP	O
responsible	responsible	JJ	B-ADJP	O
for	for	IN	B-PP	O
causing	cause	VBG	B-VP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
is	be	VBZ	B-VP	O
pneumonia	pneumonia	NN	B-NP	O
.	.	.	O	O

LIST	LIST	NN	B-NP	O
OF	OF	IN	B-PP	O
OTHER	OTHER	NNP	B-NP	O
PROBLEMS	PROBLEMS	NNP	I-NP	O
AND	AND	CC	O	O
DIAGNOSES	DIAGNOSES	NNP	B-NP	O
:	:	:	O	O
COPD	COPD	NN	B-NP	O
,	,	,	O	O
CAD	CAD	NN	B-NP	B-protein
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
TIA	TIA	NN	B-NP	B-protein
,	,	,	O	O
TVD	TVD	NN	B-NP	B-protein
,	,	,	O	O
psoriasis	psoriasis	NN	B-NP	O
.	.	.	O	O

BRIEF	BRIEF	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
70-year-old	70-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
end-stage	end-stage	JJ	B-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
on	on	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
,	,	,	O	O
COPD	COPD	NN	B-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
who	who	WP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
dyspnea	dyspnea	NN	B-NP	O
and	and	CC	I-NP	O
tachycardia	tachycardia	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
10/28/06	10/28/06	CD	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
reported	report	VBD	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
cough	cough	NN	B-NP	O
with	with	IN	B-PP	O
productive	productive	JJ	B-NP	O
sputum	sputum	NN	I-NP	O
x3	x3	NN	I-NP	O
days	day	NNS	I-NP	O
and	and	CC	O	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
pleuritic	pleuritic	JJ	B-ADJP	O
in	in	IN	B-PP	O
nature	nature	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
denied	deny	VBD	B-VP	O
any	any	DT	B-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
vomiting	vomiting	NN	B-NP	O
,	,	,	O	O
any	any	DT	B-NP	O
bowel	bowel	NN	I-NP	O
or	or	CC	I-NP	O
bladder	bladder	NN	I-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
denied	deny	VBD	B-VP	O
headache	headache	NN	B-NP	O
,	,	,	O	O
fatigue	fatigue	NN	B-NP	O
,	,	,	O	O
anorexia	anorexia	NN	B-NP	O
.	.	.	O	O

Per	Per	IN	B-PP	O
her	her	PRP$	B-NP	O
family	family	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
fever	fever	NN	I-NP	O
to	to	TO	B-PP	O
103	103	CD	B-NP	O
and	and	CC	O	O
some	some	DT	B-NP	O
confusion	confusion	NN	I-NP	O
while	while	IN	B-SBAR	O
reportedly	reportedly	RB	B-ADVP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
Emergency	Emergency	NNP	I-NP	O
Department	Department	NNP	I-NP	O
at	at	IN	B-PP	O
Re	Re	NNP	B-NP	O
Memorial	Memorial	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
tachypneic	tachypneic	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
40s	40	NNS	I-NP	O
sating	sate	VBG	B-VP	O
upper	upper	JJ	B-NP	O
80s	80	NNS	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
fingerstick	fingerstick	NN	I-NP	O
glucose	glucose	NN	I-NP	O
of	of	IN	B-PP	O
30	30	CD	B-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
ABG	ABG	NN	I-NP	O
was	be	VBD	B-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
respiratory	respiratory	JJ	I-NP	O
acidosis	acidosis	NN	I-NP	O
,	,	,	O	O
pH	pH	NN	B-NP	O
of	of	IN	B-PP	O
7.3	7.3	CD	B-NP	O
,	,	,	O	O
pCO2	pCO2	NN	B-NP	O
of	of	IN	B-PP	O
55	55	CD	B-NP	O
,	,	,	O	O
pO2	pO2	NN	B-NP	O
of	of	IN	B-PP	O
63	63	CD	B-NP	O
,	,	,	O	O
sating	sate	VBG	B-VP	O
89	89	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
2	2	CD	B-NP	O
L	L	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
admission	admission	NN	I-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
demonstrated	demonstrate	VBD	B-VP	O
an	an	DT	B-NP	O
opacity	opacity	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
base	base	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
EKG	EKG	NNP	I-NP	O
showed	show	VBD	B-VP	O
some	some	DT	B-NP	O
left-sided	left-sided	JJ	I-NP	O
strain	strain	NN	I-NP	O
unchanged	unchanged	JJ	B-ADJP	O
from	from	IN	B-PP	O
prior	prior	JJ	B-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
received	receive	VBD	B-VP	O
azithromycin	azithromycin	NN	B-NP	O
and	and	CC	I-NP	O
ceftriaxone	ceftriaxone	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
Emergency	Emergency	NNP	I-NP	O
Department	Department	NNP	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
vancomycin	vancomycin	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
BiPAP	BiPAP	NN	B-NP	B-protein
and	and	CC	O	O
transferred	transfer	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
COPD	COPD	NN	I-NP	O
flare	flare	NN	I-NP	O
with	with	IN	B-PP	O
steroids	steroid	NNS	B-NP	O
,	,	,	O	O
antibiotics	antibiotic	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
nebulizers	nebulizer	NNS	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
began	begin	VBD	B-VP	O
to	to	TO	I-VP	O
tire	tire	VB	I-VP	O
and	and	CC	O	O
developed	develop	VBD	B-VP	O
worsening	worsen	VBG	I-VP	O
hypercarbic	hypercarbic	JJ	B-NP	O
respiratory	respiratory	JJ	I-NP	O
failure	failure	NN	I-NP	O
so	so	RB	B-ADVP	O
was	be	VBD	B-VP	O
intubated	intubate	VBN	I-VP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
night	night	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
and	and	CC	O	O
extubated	extubate	VBD	B-VP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
later	later	RB	B-ADVP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
MICU	MICU	NN	I-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
AFib	AFib	NN	B-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
troponin	troponin	NN	I-NP	O
leak	leak	NN	I-NP	O
.	.	.	O	O

Otherwise	Otherwise	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
stay	stay	NN	I-NP	O
was	be	VBD	B-VP	O
unremarkable	unremarkable	JJ	B-ADJP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
extubated	extubate	VBD	B-VP	O
without	without	IN	B-PP	O
complication	complication	NN	B-NP	O
and	and	CC	O	O
transferred	transfer	VBN	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
GMS	GMS	NNP	I-NP	O
Services	Service	NNPS	I-NP	O
on	on	IN	B-PP	O
4/8/06	4/8/06	CD	B-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
End-stage	End-stage	JJ	B-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
on	on	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
Monday	Monday	NNP	B-NP	O
,	,	,	O	O
Wednesday	Wednesday	NNP	B-NP	O
and	and	CC	O	O
Friday	Friday	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
renal	renal	JJ	I-NP	O
failure	failure	NN	I-NP	O
is	be	VBZ	B-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
renal	renal	JJ	B-NP	O
artery	artery	NN	I-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

Hemodialysis	Hemodialysis	NN	B-NP	O
began	begin	VBD	B-VP	O
in	in	IN	B-PP	O
April	April	NNP	B-NP	O
2005	2005	CD	I-NP	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
with	with	IN	B-PP	O
hemoglobin	hemoglobin	NN	B-NP	B-protein
A1c	A1c	NN	I-NP	O
of	of	IN	B-PP	O
5.8	5.8	CD	B-NP	O
.	.	.	O	O

COPD	COPD	NN	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
PFTs	PFT	NNS	I-NP	B-protein
are	be	VBP	B-VP	O
available	available	JJ	B-ADJP	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

Coronary	Coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
remote	remote	JJ	B-NP	O
MI	MI	NN	I-NP	O
,	,	,	O	O
diastolic	diastolic	JJ	B-NP	O
dysfunction/CHF	dysfunction/CHF	NN	I-NP	O
.	.	.	O	O

TIA	TIA	NN	B-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
receives	receive	VBZ	B-VP	O
Coumadin	Coumadin	NNP	B-NP	O
.	.	.	O	O

Bilateral	Bilateral	JJ	B-NP	O
fem-pop	fem-pop	JJ	I-NP	O
bypasses	bypass	NNS	I-NP	O
,	,	,	O	O
psoriasis	psoriasis	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
perforated	perforated	JJ	I-NP	O
appendix	appendix	NN	I-NP	O
.	.	.	O	O

HOME	HOME	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Glyburide	Glyburide	NN	B-NP	O
5	5	CD	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
Lipitor	Lipitor	NNP	B-NP	O
10	10	CD	I-NP	O
,	,	,	O	O
PhosLo	PhosLo	NNP	B-NP	O
667	667	CD	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Zestril	Zestril	NNP	B-NP	O
60	60	CD	I-NP	O
nightly	nightly	RB	B-ADVP	O
,	,	,	O	O
Toprol-XL	Toprol-XL	NN	B-NP	O
200	200	CD	I-NP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
4	4	CD	I-NP	O
mg	mg	NN	I-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
81	81	CD	I-NP	O
,	,	,	O	O
iron	iron	NN	B-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Paxil	Paxil	NNP	B-NP	O
10	10	CD	I-NP	O
,	,	,	O	O
Nephrocaps	Nephrocaps	NNP	B-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Flovent	Flovent	NNP	B-NP	O
and	and	CC	O	O
Combivent	Combivent	NNP	B-NP	O
doses	dose	VBZ	B-VP	O
unknown	unknown	JJ	B-ADJP	O
.	.	.	O	O

TRANSFER	TRANSFER	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
TO	TO	TO	B-PP	O
THE	THE	DT	B-NP	O
GMS	GMS	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
Diltiazem	Diltiazem	NNP	B-NP	O
90	90	CD	B-NP	O
p.o.	p.o.	NN	I-NP	O
q.i.d.	q.i.d.	NNP	B-NP	O
,	,	,	O	O
Lopressor	Lopressor	NNP	B-NP	O
37.5	37.5	CD	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
albuterol	albuterol	NN	B-NP	O
,	,	,	O	O
PhosLo	PhosLo	NNP	B-NP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
,	,	,	O	O
Pepcid	Pepcid	NNP	B-NP	O
,	,	,	O	O
insulin	insulin	NN	B-NP	O
NPH	NPH	NN	I-NP	O
15	15	CD	B-NP	O
units	unit	NNS	I-NP	O
b.i.d.	b.i.d.	NN	B-NP	O
,	,	,	O	O
Nicotine	Nicotine	NN	B-NP	O
patch	patch	NN	I-NP	O
,	,	,	O	O
nystatin	nystatin	NN	B-NP	O
,	,	,	O	O
prednisone	prednisone	NN	B-NP	O
taper	taper	NN	I-NP	O
,	,	,	O	O
betamethasone	betamethasone	NN	B-NP	O
,	,	,	O	O
captopril	captopril	NN	B-NP	O
50	50	CD	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	B-protein
2	2	CD	I-NP	I-protein
,	,	,	O	O
simvastatin	simvastatin	NN	B-NP	O
20	20	CD	I-NP	O
,	,	,	O	O
an	an	DT	B-NP	O
Aspart	Aspart	NNP	I-NP	O
sliding	slide	VBG	I-NP	O
scale	scale	NN	I-NP	O
and	and	CC	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
lactulose	lactulose	NN	I-NP	O
,	,	,	O	O
Zyprexa	Zyprexa	NNP	B-NP	O
and	and	CC	I-NP	O
Ativan	Ativan	NNP	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
no	no	DT	B-NP	O
known	know	VBN	I-NP	O
drug	drug	NN	I-NP	O
allergies	allergy	NNS	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
an	an	DT	B-NP	O
active	active	JJ	I-NP	O
smoker	smoker	NN	I-NP	O
,	,	,	O	O
smokes	smoke	VBZ	B-VP	O
about	about	IN	B-PP	O
a	a	DT	B-NP	O
pack	pack	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
half	half	PDT	I-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
55	55	CD	I-NP	O
years	year	NNS	I-NP	O
.	.	.	O	O

Lives	Life	NNS	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
daughter	daughter	NN	I-NP	O
,	,	,	O	O
has	have	VBZ	B-VP	O
9	9	CD	B-NP	O
children	child	NNS	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAM	EXAM	NN	I-NP	O
UPON	UPON	NN	I-NP	O
TRANSFER	TRANSFER	NN	I-NP	O
TO	TO	TO	B-PP	O
THE	THE	DT	B-NP	O
GMS	GMS	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
:	:	:	O	O
Weight	Weight	NNP	B-NP	O
92.9	92.9	CD	I-NP	O
,	,	,	O	O
temperature	temperature	NN	B-NP	O
is	be	VBZ	B-VP	O
96.2	96.2	CD	B-NP	O
,	,	,	O	O
heart	heart	NN	B-NP	B-protein
rate	rate	NN	I-NP	I-protein
118	118	CD	I-NP	I-protein
AFib	AFib	NN	I-NP	I-protein
,	,	,	O	O
BP	BP	NN	B-NP	B-DNA
107/57	107/57	CD	I-NP	I-DNA
,	,	,	O	O
sating	sate	VBG	B-VP	O
95	95	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
2	2	CD	B-NP	O
L	L	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
general	general	JJ	B-ADJP	O
,	,	,	O	O
she	she	PRP	B-NP	O
appeared	appear	VBD	B-VP	O
younger	young	JJR	B-ADJP	O
than	than	IN	B-PP	O
stated	state	VBN	B-NP	O
age	age	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
psoriatic	psoriatic	JJ	I-NP	O
rash	rash	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
thigh	thigh	NN	I-NP	O
.	.	.	O	O

Neuro	Neuro	NNP	B-NP	O
exam	exam	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
hard	hard	RB	B-ADVP	O
of	of	IN	B-PP	O
hearing	hearing	NN	B-NP	O
,	,	,	O	O
otherwise	otherwise	RB	B-ADVP	O
her	her	PRP$	B-NP	O
cranial	cranial	JJ	I-NP	O
nerves	nerve	NNS	I-NP	O
were	be	VBD	B-VP	O
intact	intact	JJ	B-ADJP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
alert	alert	JJ	B-ADJP	O
and	and	CC	O	O
oriented	orient	VBN	B-VP	O
x3	x3	NN	B-NP	O
.	.	.	O	O

Head	Head	NN	B-NP	O
and	and	CC	I-NP	O
neck	neck	NN	I-NP	O
exam	exam	NN	I-NP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
JVP	JVP	NN	B-NP	B-protein
of	of	IN	B-PP	O
5	5	CD	B-NP	O
cm	cm	NN	I-NP	O
of	of	IN	B-PP	O
water	water	NN	B-NP	O
.	.	.	O	O

Mucous	Mucous	JJ	B-NP	O
membranes	membrane	NNS	I-NP	O
were	be	VBD	B-VP	O
moist	moist	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
oropharynx	oropharynx	NN	I-NP	O
was	be	VBD	B-VP	O
clear	clear	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
extraocular	extraocular	JJ	I-NP	O
motions	motion	NNS	I-NP	O
were	be	VBD	B-VP	O
full	full	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
exam	exam	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
rhythm	rhythm	NN	I-NP	O
without	without	IN	B-PP	O
appreciable	appreciable	JJ	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	O	O
rubs	rub	NNS	B-NP	O
or	or	CC	I-NP	O
gallops	gallop	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
heaves	heave	NNS	I-NP	O
.	.	.	O	O

Lungs	Lung	NNS	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
expiratory	expiratory	JJ	B-NP	O
wheezing	wheezing	NN	I-NP	O
without	without	IN	B-PP	O
rhonchi	rhonchus	NNS	B-NP	O
or	or	CC	I-NP	O
crackles	crackle	NNS	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
,	,	,	O	O
although	although	IN	B-SBAR	O
distended	distended	JJ	B-ADJP	O
but	but	CC	I-ADJP	O
soft	soft	JJ	I-ADJP	O
,	,	,	O	O
no	no	DT	B-NP	O
laparotomy	laparotomy	NN	I-NP	O
scar	scar	NN	I-NP	O
,	,	,	O	O
normoactive	normoactive	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	VBZ	B-VP	O
without	without	IN	B-PP	O
guarding	guard	VBG	B-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
Port-A-Cath	Port-A-Cath	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
right	right	JJ	I-NP	O
chest	chest	NN	I-NP	O
that	that	WDT	B-NP	O
appeared	appear	VBD	B-VP	O
clean	clean	JJ	B-ADJP	O
,	,	,	I-ADJP	O
dry	dry	JJ	I-ADJP	O
and	and	CC	I-ADJP	O
intact	intact	JJ	I-ADJP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
TEDs	TED	NNS	B-NP	O
and	and	CC	I-NP	O
SCDs	SCD	NNS	I-NP	O
,	,	,	O	O
bilateral	bilateral	JJ	B-NP	O
pedal	pedal	JJ	I-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
they	they	PRP	B-NP	O
were	be	VBD	B-VP	O
warm	warm	JJ	B-ADJP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
PROBLEM	PROBLEM	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

From	From	IN	B-PP	O
a	a	DT	B-NP	O
Pulmonary	Pulmonary	JJ	I-NP	O
Standpoint	Standpoint	NN	I-NP	O
:	:	:	O	O
Pneumonia/COPD	Pneumonia/COPD	NN	B-NP	O
flare	flare	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
and	and	CC	I-NP	O
COPD	COPD	NN	I-NP	O
flare	flare	NN	I-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
needed	need	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
intubated	intubate	VBN	I-VP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
short	short	JJ	I-NP	O
MICU	MICU	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
did	do	VBD	B-VP	O
well	well	RB	B-ADVP	O
on	on	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
from	from	IN	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
,	,	,	O	O
azithromycin	azithromycin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
vancomycin	vancomycin	NN	B-NP	O
to	to	TO	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
completed	complete	VBD	B-VP	O
a	a	DT	B-NP	O
ten-day	ten-day	JJ	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
also	also	RB	B-ADVP	O
started	start	VBD	B-VP	O
on	on	IN	B-PP	O
steroid	steroid	NN	B-NP	O
taper	taper	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
leave	leave	VB	I-VP	O
with	with	IN	B-PP	O
20	20	CD	B-NP	O
mg	mg	NN	I-NP	O
of	of	IN	B-PP	O
prednisone	prednisone	NN	B-NP	O
for	for	IN	B-PP	O
two	two	CD	B-NP	O
more	more	JJR	I-NP	O
days	day	NNS	I-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
10	10	CD	B-NP	O
mg	mg	NN	I-NP	O
of	of	IN	B-PP	O
prednisone	prednisone	NN	B-NP	O
for	for	IN	B-PP	O
three	three	CD	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

Upon	Upon	IN	B-PP	O
transfer	transfer	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
Combivent	Combivent	NNP	B-NP	O
and	and	CC	I-NP	O
Flovent	Flovent	NNP	I-NP	O
and	and	CC	O	O
received	receive	VBD	B-VP	O
p.r.n.	p.r.n.	NN	B-NP	O
albuterol	albuterol	NN	I-NP	O
nebulizers	nebulizer	NNS	I-NP	O
and	and	CC	O	O
albuterol	albuterol	NN	B-NP	O
inhaler	inhaler	NN	I-NP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
q.	q.	NN	I-NP	O
4	4	CD	I-NP	O
basis	basis	NN	I-NP	O
.	.	.	O	O

Smoking	Smoking	NN	B-NP	O
cessation	cessation	NN	I-NP	O
was	be	VBD	B-VP	O
emphasized	emphasize	VBN	I-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
.	.	.	O	O

Ace	Ace	NN	B-NP	O
consult	consult	NN	I-NP	O
was	be	VBD	B-VP	O
called	call	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
nicotine	nicotine	NN	I-NP	O
patch	patch	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
a	a	DT	B-NP	O
flu	flu	NN	I-NP	O
vaccine	vaccine	NN	I-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
blood	blood	NN	I-NP	O
cultures	culture	NNS	I-NP	O
and	and	CC	O	O
sputum	sputum	NN	B-NP	O
cultures	culture	NNS	I-NP	O
were	be	VBD	B-VP	O
unrevealing	unrevealing	JJ	B-ADJP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
O2	O2	NN	I-NP	O
saturation	saturation	NN	I-NP	O
was	be	VBD	B-VP	O
titrated	titrate	VBN	I-VP	O
to	to	TO	B-PP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
93	93	CD	I-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

From	From	IN	B-PP	O
an	an	DT	B-NP	O
endocrine	endocrine	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
fleetingly	fleetingly	RB	I-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
Portland	Portland	NNP	B-NP	O
protocol	protocol	NN	I-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
MICU	MICU	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
NPH	NPH	NN	B-NP	B-protein
15	15	CD	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
insulin	insulin	NN	I-NP	I-protein
and	and	CC	I-NP	O
NovoLog	NovoLog	NN	I-NP	O
sliding	slide	VBG	I-NP	O
scale	scale	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
should	should	MD	B-VP	O
continue	continue	VB	I-VP	O
her	her	PRP$	B-NP	O
aspirin	aspirin	NN	I-NP	O
and	and	CC	I-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
and	and	CC	O	O
later	later	RB	B-ADVP	O
her	her	PRP$	B-NP	O
hemoglobin	hemoglobin	NN	I-NP	B-protein
A1c	A1c	NN	I-NP	O
was	be	VBD	B-VP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
very	very	RB	B-NP	O
well	well	RB	I-NP	O
controlled	control	VBN	I-NP	O
diabetic	diabetic	JJ	B-ADJP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

From	From	IN	B-PP	O
a	a	DT	B-NP	O
cardiovascular	cardiovascular	JJ	I-NP	O
standpoint	standpoint	NN	I-NP	O
:	:	:	O	O
A.	A.	NNP	B-NP	O
Ischemia	Ischemia	NNP	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
troponin	troponin	NN	I-NP	O
peaked	peak	VBD	B-VP	O
to	to	TO	B-PP	O
0.38	0.38	CD	B-NP	O
on	on	IN	B-PP	O
11/22/06	11/22/06	CD	B-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
associated	associate	VBN	I-VP	O
with	with	IN	B-PP	O
any	any	DT	B-NP	O
dynamic	dynamic	JJ	I-NP	O
EKG	EKG	NN	I-NP	O
changes	change	NNS	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
EKG	EKG	NN	I-NP	B-protein
does	do	VBZ	B-VP	O
show	show	VB	I-VP	O
some	some	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
strain	strain	NN	B-NP	O
versus	versus	CC	O	O
infralateral	infralateral	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
with	with	IN	B-PP	O
T-waves	T-wave	NNS	B-NP	O
inversions	inversion	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
inferior	inferior	JJ	I-NP	O
and	and	CC	I-NP	O
lateral	lateral	JJ	I-NP	O
leads	lead	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
troponin	troponin	NN	I-NP	O
trended	trend	VBD	B-VP	O
down	down	RB	B-ADVP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
and	and	CC	B-PP	O
on	on	IN	B-PP	O
last	last	JJ	B-NP	O
check	check	NN	I-NP	O
were	be	VBD	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
0.2	0.2	CD	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
whether	whether	IN	B-SBAR	O
this	this	DT	B-NP	O
leak	leak	NN	I-NP	O
was	be	VBD	B-VP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
versus	versus	IN	B-PP	O
infection	infection	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
aspirin	aspirin	NN	I-NP	O
,	,	,	O	O
statin	statin	NN	B-NP	O
,	,	,	O	O
beta-blocker	beta-blocker	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
ACE	ACE	NN	B-NP	O
were	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
fasting	fasting	JJ	I-NP	O
lipid	lipid	NN	I-NP	O
profile	profile	NN	I-NP	O
was	be	VBD	B-VP	O
remarkable	remarkable	JJ	B-ADJP	O
only	only	RB	B-ADVP	O
for	for	IN	B-PP	O
hypertriglyceridemia	hypertriglyceridemia	NN	B-NP	O
and	and	CC	I-NP	O
HDL	HDL	NN	I-NP	O
of	of	IN	B-PP	O
38	38	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
scheduled	schedule	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
nuclear	nuclear	JJ	I-NP	O
medicine	medicine	NN	I-NP	O
stress	stress	NN	I-NP	O
test	test	NN	I-NP	O
on	on	IN	B-PP	O
8/13/06	8/13/06	CD	B-NP	O
at	at	IN	B-PP	O
09	09	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
a.m.	a.m.	RB	I-NP	O
B.	B.	NNP	I-NP	O
Rate	Rate	NNP	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
AFib	AFib	NN	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
and	and	CC	I-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
controlled	control	VBN	I-VP	O
with	with	IN	B-PP	O
diltiazem	diltiazem	NN	B-NP	O
and	and	CC	I-NP	O
Lopressor	Lopressor	NN	I-NP	O
titrated	titrate	VBN	B-VP	O
to	to	TO	B-PP	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
80	80	CD	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
monitored	monitor	VBN	I-VP	O
on	on	IN	B-PP	O
tele	tele	NN	B-NP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
already	already	RB	B-ADVP	O
in	in	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
for	for	IN	B-PP	O
TIAs	TIA	NNS	B-NP	B-protein
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
new	new	JJ	I-NP	O
INR	INR	NN	I-NP	O
goal	goal	NN	I-NP	O
for	for	IN	B-PP	O
her	her	PRP	B-NP	O
is	be	VBZ	B-VP	O
between	between	IN	B-NP	O
2	2	CD	I-NP	O
and	and	CC	I-NP	O
3	3	CD	I-NP	O
and	and	CC	I-NP	O
Coumadin	Coumadin	NN	I-NP	O
levels	level	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
checked	check	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
.	.	.	O	O

C.	C.	NNP	B-NP	O
Pump	Pump	NNP	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
EF	EF	NN	I-NP	B-protein
was	be	VBD	B-VP	O
55	55	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
echo	echo	NN	B-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
done	do	VBN	I-VP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
some	some	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
aortic	aortic	JJ	B-NP	O
sclerosis	sclerosis	NN	I-NP	O
,	,	,	O	O
otherwise	otherwise	RB	B-ADVP	O
,	,	,	O	O
there	there	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
or	or	CC	I-NP	O
wall	wall	NN	I-NP	O
motion	motion	NN	I-NP	O
abnormalities	abnormality	NNS	I-NP	O
noted	note	VBD	B-VP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

From	From	IN	B-PP	O
a	a	DT	B-NP	O
hematologic	hematologic	JJ	I-NP	O
standpoint	standpoint	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
epopoietin	epopoietin	NN	B-NP	B-protein
for	for	IN	B-PP	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
of	of	IN	B-PP	O
35	35	CD	B-NP	O
dropped	drop	VBD	B-VP	O
to	to	TO	B-PP	O
26	26	CD	B-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
and	and	CC	O	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
a	a	DT	B-NP	O
unit	unit	NN	I-NP	O
of	of	IN	B-PP	O
blood	blood	NN	B-NP	O
for	for	IN	B-PP	O
that	that	DT	B-NP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
that	that	DT	B-NP	O
transfusion	transfusion	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
was	be	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
lower	low	JJR	I-NP	O
to	to	TO	B-VP	O
mid	mid	VB	I-VP	O
30s	30s	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
iron	iron	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
takes	take	VBZ	B-VP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
stool	stool	NN	I-NP	O
is	be	VBZ	B-VP	O
guaiac	guaiac	JJ	B-ADJP	O
negative	negative	JJ	B-ADJP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

From	From	IN	B-PP	O
a	a	DT	B-NP	O
GI	GI	NN	I-NP	O
perspective	perspective	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
mild	mild	JJ	I-NP	O
transaminitis	transaminitis	NN	I-NP	O
noted	note	VBN	B-VP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
thought	think	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
hepatic	hepatic	JJ	B-NP	O
congestion	congestion	NN	I-NP	O
.	.	.	O	O

Viral	Viral	JJ	B-NP	O
serologies	serology	NNS	I-NP	O
were	be	VBD	B-VP	O
drawn	draw	VBN	I-VP	O
including	include	VBG	B-PP	O
hep	hep	NN	B-NP	B-DNA
B	B	NN	I-NP	I-DNA
and	and	CC	O	O
C	C	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
transaminitis	transaminitis	NN	I-NP	O
resolved	resolve	VBN	B-VP	O
on	on	IN	B-PP	O
its	its	PRP$	B-NP	O
own	own	JJ	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

From	From	IN	B-PP	O
a	a	DT	B-NP	O
dermatologic	dermatologic	JJ	I-NP	O
perspective	perspective	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
psoriasis	psoriasis	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
topical	topical	JJ	B-NP	O
steroids	steroid	NNS	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
effect	effect	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

From	From	IN	B-PP	O
an	an	DT	B-NP	O
infectious	infectious	JJ	I-NP	O
disease	disease	NN	I-NP	O
standpoint	standpoint	NN	I-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
evidence	evidence	NN	B-NP	O
of	of	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
by	by	IN	B-PP	O
clinical	clinical	JJ	B-NP	O
exam	exam	NN	I-NP	O
and	and	CC	I-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
on	on	IN	B-PP	O
admisison	admisison	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
resolved	resolve	VBN	I-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
completed	complete	VBD	B-VP	O
a	a	DT	B-NP	O
ten-day	ten-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
multiple	multiple	JJ	B-NP	B-cell_line
cultures	culture	NNS	I-NP	I-cell_line
were	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
MICU	MICU	NN	I-NP	B-DNA
including	include	VBG	B-PP	O
that	that	IN	B-SBAR	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
A	A	NN	I-NP	B-cell_line
line	line	NN	I-NP	I-cell_line
which	which	WDT	B-NP	O
grew	grow	VBD	B-VP	O
out	out	RP	B-PRT	O
coag-negative	coag-negative	JJ	B-NP	O
staph	staph	NN	I-NP	O
thought	think	VBD	B-VP	O
likely	likely	JJ	B-ADJP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
a	a	DT	B-NP	O
contaminate	contaminate	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Neuro	Neuro	NNP	B-NP	O
exam	exam	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
alert	alert	JJ	B-NP	O
and	and	CC	I-NP	O
oriented	oriented	JJ	I-NP	O
and	and	CC	I-NP	O
intact	intact	JJ	I-NP	O
upon	upon	IN	B-PP	O
transfer	transfer	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
medical	medical	JJ	I-NP	O
service	service	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
TIAs	TIA	NNS	B-NP	B-protein
her	her	PRP$	B-NP	I-protein
Coumadin	Coumadin	NN	I-NP	I-protein
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
renal	renal	JJ	I-NP	O
diabetic	diabetic	JJ	I-NP	O
low-fat	low-fat	JJ	I-NP	O
diet	diet	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
fluid	fluid	JJ	B-ADJP	O
restricted	restricted	JJ	B-ADJP	O
to	to	TO	B-PP	O
2	2	CD	B-NP	O
L	L	NN	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
Monday	Monday	NNP	B-NP	O
,	,	,	O	O
Wednesday	Wednesday	NNP	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Friday	Friday	NNP	B-NP	O
for	for	IN	B-PP	O
end-stage	end-stage	JJ	B-NP	O
renal	renal	JJ	I-NP	O
disease	disease	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
RAS	RAS	NN	B-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
followed	follow	VBN	I-VP	O
by	by	IN	B-PP	O
renal	renal	JJ	O	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
renal	renal	JJ	I-NP	O
attending	attend	VBG	I-NP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Neutra-Phos	Neutra-Phos	NNP	B-NP	O
,	,	,	O	O
Nephrocaps	Nephrocaps	NNP	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
PhosLo	PhosLo	NN	I-NP	B-protein
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
calcium	calcium	NN	I-NP	O
and	and	CC	I-NP	O
phosphorus	phosphorus	NN	I-NP	O
were	be	VBD	B-VP	O
monitored	monitor	VBN	I-VP	O
q.a.m.	q.a.m.	NN	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
IPTH	IPTH	NN	I-NP	O
was	be	VBD	B-VP	O
checked	check	VBN	I-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
415	415	CD	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Prophylaxis	Prophylaxis	NN	B-NP	O
.	.	.	O	O

Heparin	Heparin	NN	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
subcu	subcu	NN	B-NP	O
until	until	IN	B-PP	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
therapeutic	therapeutic	JJ	B-ADJP	O
.	.	.	O	O

She	She	PRP	B-NP	O
still	still	RB	B-ADVP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
VRE	VRE	NN	B-NP	O
precautions	precaution	NNS	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
positive	positive	JJ	I-NP	B-protein
rectal	rectal	JJ	I-NP	I-protein
swab	swab	NN	I-NP	I-protein
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
full	full	JJ	I-NP	O
code	code	NN	I-NP	O
.	.	.	O	O

Discharge	Discharge	NN	B-NP	O
medications	medication	NNS	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
included	include	VBN	I-VP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
addendum	addendum	NN	I-NP	O
.	.	.	O	O

PRIMARY	PRIMARY	NN	B-NP	O
CARE	CARE	NN	I-NP	O
PHYSICIAN	PHYSICIAN	NN	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Scadden	Scadden	NNP	I-NP	O
at	at	IN	B-PP	O
CCMH	CCMH	NNP	B-NP	O
eScription	eScription	NN	I-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
2-1030834	2-1030834	CD	B-NP	O
CSSten	CSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
LAAKER	LAAKER	NN	B-NP	O
,	,	,	O	O
CALVIN	CALVIN	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
GETTY	GETTY	NNP	B-NP	O
,	,	,	O	O
KARL	KARL	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
2025908	2025908	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
5/18/06	5/18/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
5/18/06	5/18/06	CD	B-NP	O

